Results 251 to 260 of about 379,495 (290)

Toward a working definition of ketogenic diet resistance in GLUT1 deficiency syndrome

open access: yesEpileptic Disorders, EarlyView.
Abstract Objective The ketogenic diet (KD) is the standard treatment for glucose transporter type 1 deficiency syndrome (GLUT1‐DS), typically yielding seizure reduction and cognitive/motor gains. However, a small subset of patients shows limited or no clinical benefit.
Raffaele Falsaperla   +8 more
wiley   +1 more source

An unusual case of ischemic stroke resulting from hyoid bone compression of the internal carotid artery. [PDF]

open access: yesRadiol Case Rep
El Yaagoubi N   +8 more
europepmc   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

open access: yesEpilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

HIV incidence trends in Brazil and neighboring countries: an ecological and analytical study on public health. [PDF]

open access: yesFront Public Health
Dos Anjos TAF   +8 more
europepmc   +1 more source

Epilepsy syndromes classification

open access: yesEpilepsia Open, EarlyView.
Abstract Epilepsy syndromes are distinct electroclinical entities which have been recently defined by the International League Against Epilepsy Nosology and Definitions Task Force. Each syndrome is associated with “a characteristic cluster of clinical and EEG features, often supported by specific etiologic findings”.
Elaine C. Wirrell   +4 more
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

open access: yesEpilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy